Abstract
Key Points Transcatheter aortic valve replacement using the current commercially available devices in the United States for aortic regurgitation is considered off label use. Pure aortic regurgitation is different from aortic stenosis due to associated aortic annular dilation/aortopathy and relative lack of calcium on the leaflets and annulus. Patients with pure aortic regurgitation undergoing transcatheter aortic valve replacement using commercially available valve platforms are more likely to have unfavorable outcomes than the typical aortic stenosis patients. The evolving valve platforms, inclusive of active leaflet fixation may be ultimately more suited for transcatheter management of pure aortic regurgitation; clinical investigation is ongoing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
